CXCR4(S338X) clonality is an important determinant of ibrutinib outcomes in patients with Waldenström macroglobulinemia

CXCR4(S338X) clonality ≥25% is associated with lower very good partial response and shorter progression-free survival to ibrutinib. CXCR4(S338X) clonality assessment represents a novel biomarker to predict outcomes to ibrutinib in Waldenström macroglobulinemia patients.

Guardado en:
Detalles Bibliográficos
Publicado en:Blood Adv
Autores principales: Gustine, Joshua N., Xu, Lian, Tsakmaklis, Nicholas, Demos, Maria G., Kofides, Amanda, Chen, Jiaji G., Liu, Xia, Munshi, Manit, Guerrera, Maria Luisa, Chan, Gloria G., Patterson, Christopher J., Keezer, Andrew, Meid, Kirsten, Dubeau, Toni, Yang, Guang, Hunter, Zachary R., Treon, Steven P., Castillo, Jorge J.
Formato: Artigo
Lenguaje:Inglês
Publicado: American Society of Hematology 2019
Materias:
Stimulus Report
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6784519/
https://ncbi.nlm.nih.gov/pubmed/31570491
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2019000635
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares